Anixa Biosciences INC 8-K filings

Anixa Biosciences announced encouraging patient survival data and regulatory approval for dose escalation in its Phase 1 ovarian cancer CAR-T clinical trial.

Anixa Biosciences announced positive final Phase 1 clinical trial data for its investigational breast cancer vaccine, meeting primary endpoints and showing immune response.

Anixa Biosciences successfully held its 2025 annual meeting, resulting in the re-election of directors, approval of executive compensation, and ratification of the accounting firm appointment.

Anixa Biosciences and Cleveland Clinic presented updated positive data from their Phase 1 breast cancer vaccine trial, showing promising immune responses and safety across multiple cohorts.

Anixa Biosciences has entered into a joint development agreement with Cleveland Clinic to develop novel vaccines for various cancer types, expanding their existing collaboration.

Anixa Biosciences successfully held its 2024 annual meeting, re-electing four directors, approving executive compensation on an advisory basis, and ratifying its independent auditor.